Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.31 |
| ▸ | CYBB | P04839 | 1/20 | 0.31 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.31 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11892669 | 0.77 | CRHR1 (0.35) | NOX1CYBBNOX3NOX4 | |
| SCHEMBL3026252 | 0.76 | NOX1 (0.35) | NOX1CYBBNOX3NOX4 | |
| Hydrochloric Acid SCHEMBL3035612 | 0.75 | NOX1 (0.35) | NOX1CYBBNOX3NOX4 | |
| SCHEMBL11892660 | 0.75 | TP53 (0.38) | NOX1CYBBNOX3NOX4 | |
| SCHEMBL3035317 | 0.75 | NOX1 (0.43) | NOX1CYBBNOX3NOX4 | |
| SCHEMBL10476547 | 0.74 | TERT (0.39) | NOX1CYBBNOX3NOX4 | |
| SCHEMBL16848275 | 0.73 | MEN1 (0.34) | NOX1 | |
| SCHEMBL3033362 | 0.72 | KDM1A (0.40) | — | |
| SCHEMBL3031844 | 0.70 | — | — | |
| SCHEMBL7717528 | 0.69 | DUT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067900-B2 | Diaminophenothiazine compounds, a method for preparing same and uses thereof | PHARMA HYDRO DEVELOPMENT—P.H.D. (FR) | 2015-06-30 | — | — | US | disclosed |
| EP-2185531-B1 | Diaminophenothiazine compounds, a method for preparing same and uses thereof | PHARMA HYDRO DEV P H D (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20100204215-A1 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2185531-A2 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | Pharma Hydro Development - P.H.D. (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009044054-A2 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | PHARMA HYDRO DEVELOPMENT - P.H.D. (FR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204215-A1 | NOVEL DIAMINOPHENOTHIAZINE COMPOUNDS, A METHOD FOR PREPARING SAME AND USES THEREOF | AOC1, DDT, DDC | NOX1 143/4885CYBB 292/4885NOX3 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.